Functional antibodies produced by oncolytic clostridia

Area of Science:

• Oncology
• Microbiology
• Biotechnology

Background:

• Intratumoral hypoxia is common in solid tumors, promoting cancer cell survival and resistance to therapies.
• Hypoxia-inducible factor 1-alpha (HIF-1alpha) is a critical regulator of the hypoxic response and a potential therapeutic target.
• Clostridium-based oncolysis utilizes bacteria to target and destroy tumor cells in hypoxic environments.

Purpose of the Study:

• To develop a novel therapeutic strategy for hypoxic solid tumors.
• To engineer Clostridium strains capable of delivering targeted therapies against HIF-1alpha.
• To establish a foundation for Clostridium-directed antibody therapy (CDAT).

Main Methods:

• Isolation of transconjugants from two Clostridium strains (C. novyi-NT and C. sporogenes).
• Engineering these strains to express single-chain antibodies specific for human HIF-1alpha.
• Utilizing Clostridium's natural tumor-homing ability.

Main Results:

• Successful isolation of engineered Clostridium strains expressing HIF-1alpha-specific antibodies.
• Demonstration of a novel approach for Clostridium-directed antibody therapy (CDAT).
• Potential for targeting resistant tumor regions.

Conclusions:

• Engineered Clostridium strains represent a promising platform for targeted cancer therapy.
• CDAT offers a novel strategy to deliver therapeutics to hypoxic tumor cores.
• This approach may overcome resistance to radio- and chemotherapy.